GSK shares fell after a Food and Drug Administration advisory committee voted against approval of the company's Blenrep drug, a setback for its bid to reintroduce the blood-cancer treatment in the U.S ...

The enterprise suite introduces four key AI agents – finance, payments, accounting and project management – each designed to ...

GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine segment. See why the stock is a Buy.

Oncologic Drugs Advisory Committee has voted against two proposed combination regimens containing GSK’s Blenrep (belantamab ...

This summary highlights significant events in the health sector, including Johnson & Johnson's profit boost from Darzalex, safety concerns for GSK's cancer drug, refugee malnutrition in Gaza, KKR's ...

Explore Matthews International Corporation's restructuring efforts, asset sales, and challenges in reducing debt. Click for ...

Rather than chase enterprise contracts with large hospital systems, Freed has focused on small clinics and solo practitioners.

OPEN The FTSE 100 was expected to open 9.7 points lower ahead of the bell on Monday after wrapping up the previous session 0.38% softer at 8,941.12.

The rising occurrence of dysmenorrhea, along with greater awareness and advancements in diagnosis, is driving substantial growth in the dysmenorrhea ...

The melanoma market is predicted to surge during the forecast period (2025–2034) owing to factors, as the increasing incidence of melanoma, the launc ...

The FTSE 100 index closed down 18.06 points, 0.2%, at 9,120.31. The FTSE 250 closed 37.43 points lower, 0.2%, at 22,117.98, and the AIM All-Share closed down 0.23 of a point at 776.64.